CVE-2024-54239 identifies a Missing Authorization vulnerability in the dugudlabs Eyewear prescription form, affecting versions up to 4.0.18. The vulnerability stems from the eyewear-prescription-form component failing to enforce proper authorization checks, allowing unauthorized users to perform actions reserved for privileged users, resulting in privilege escalation. This means an attacker could potentially access or modify sensitive prescription data or administrative settings without proper permissions. The vulnerability does not require prior authentication or user interaction, increasing its risk profile. Although no known exploits are currently in the wild, the flaw's presence in a healthcare-related application handling sensitive personal data raises significant concerns. The lack of a CVSS score necessitates an independent severity assessment, which rates this issue as high due to the potential impact on confidentiality, integrity, and availability of sensitive data, combined with the ease of exploitation. The vulnerability affects organizations using dugudlabs Eyewear prescription form software, particularly those in healthcare, eyewear retail, and related sectors. The absence of patch links suggests that fixes may be pending or not yet publicly released, underscoring the need for proactive mitigation. The vulnerability was published on December 13, 2024, with the initial reservation on December 2, 2024, indicating recent discovery and disclosure. The technical details confirm the missing authorization as the root cause, with no additional CWE identifiers provided. Overall, this vulnerability represents a critical risk to the confidentiality and integrity of eyewear prescription data and associated administrative functions.

The primary impact of CVE-2024-54239 is unauthorized privilege escalation within the affected dugudlabs Eyewear prescription form application. This can lead to unauthorized access to sensitive personal health information, including eyewear prescriptions, potentially violating privacy regulations such as HIPAA or GDPR. Attackers could manipulate prescription data, disrupt service availability, or gain administrative control over the application, undermining trust and operational integrity. For organizations, this could result in data breaches, regulatory fines, reputational damage, and operational disruptions. The vulnerability's ease of exploitation without authentication increases the risk of widespread abuse, especially in environments where the eyewear-prescription-form is exposed to untrusted users or integrated into larger healthcare systems. Given the sensitive nature of healthcare data, the impact extends beyond technical compromise to legal and compliance consequences. Additionally, if exploited in a supply chain context, it could affect multiple downstream organizations relying on this software. The lack of known exploits in the wild currently limits immediate impact but does not reduce the urgency for remediation.

Organizations should immediately audit their use of the dugudlabs Eyewear prescription form and identify affected versions (up to 4.0.18). Until an official patch is released, implement strict network segmentation and access controls to restrict exposure of the eyewear-prescription-form interface to trusted users only. Conduct thorough code reviews and penetration testing focused on authorization logic to identify and remediate missing checks. Employ Web Application Firewalls (WAFs) with custom rules to detect and block unauthorized access attempts targeting the prescription form endpoints. Monitor logs for unusual access patterns indicative of privilege escalation attempts. Engage with dugudlabs for timely patch updates and apply them promptly once available. Additionally, enforce multi-factor authentication and least privilege principles for all users interacting with the eyewear prescription system. Educate staff on the risks and signs of exploitation. Finally, prepare incident response plans specific to potential data breaches involving healthcare data to minimize impact if exploitation occurs.